ALB and kidney failure: Indeed, TDM, which consists of measuring the patients’ plasma concentration of cefazolin, is the only way to accurately determine each patient’s individual CL, as well as to take into account each patient’s specificities (27) that cannot be precisely anticipated a priori, such as protein binding change because of serum albumin concentration variation, fluctuating Vd due to kidney failure, to dialysis sessions, frequent denutrition, sarcopenia, and so on.